Lv2
140 积分 2022-05-07 加入
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
22天前
已完结
Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer
30天前
已完结
Bulumtatug Fuvedotin (BFv, 9MW2821), a next-generation Nectin-4 targeting antibody–drug conjugate, in patients with advanced solid tumors: a first-in-human, open-label, multicenter, phase I/II study
1个月前
已完结
Bulumtatug Fuvedotin (BFv, 9MW2821), a next-generation Nectin-4 targeting antibody–drug conjugate, in patients with advanced solid tumors: a first-in-human, open-label, multicenter, phase I/II study
1个月前
已完结
Efficacy and Safety of BL-B01D1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma: A Phase II Clinical Trial
1个月前
已完结
Reconsidering adjuvant and perioperative immune-checkpoint inhibition: de-escalation, expansion and personalization
5个月前
已完结
Second-line treatment options in metastatic castration-resistant prostate cancer after progression on first-line androgen-receptor targeting therapies: A systematic review and Bayesian network analysis
5个月前
已完结
Taxanes Versus Androgen Receptor Therapy as Second-Line Treatment for Castrate-Resistant Metastatic Prostate Cancer After First-Line Androgen Receptor Therapy
5个月前
已完结
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
6个月前
已完结
New promises and challenges in the treatment of advanced non-small-cell lung cancer
6个月前
已完结
皖公网安备34019202002308
